

RWANDA
Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda		
2. Grant number: 17-RWA-34a-X / 17-RWA-35a-Y		
3. Date of Decision Letter: 13 June 2017		
4. Date of the Partnership Framework Agreement: 7 June 2013		
5. Programme title: NVS, Measles-Rubella Follow-up campaign		
6. Vaccine type: Measles rubella		
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED		
8. Programme duration¹: 2017		
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)		
	2017	Total ²
Programme Budget (US\$)	US\$990,500	US\$990,500
10. Vaccine introduction grant (in US\$): Not applicable		
11. Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³		
Type of supplies to be purchased with Gavi funds in each year		2017
Number of Measles-Rubella vaccines doses		1,577,000
Annual Amounts (US\$)		US\$990,500
12. Procurement agency: UNICEF		
13. Self-procurement: Not applicable		
14. Co-financing obligations: Not applicable		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

15. Operational support for campaigns: The support for operational costs for campaign will be disbursed in cash to the MoH.

	2017
Grant amount (US\$)	US\$923,500*

* US\$923,500 is the maximum ceiling approved by Gavi for this support; Final amount budgeted for by Rwanda which will be disbursed by Gavi is **US\$923,434**.

16. Additional reporting requirements: Not applicable

In accordance with applicable Gavi processes, Rwanda shall report on programmatic and financial performance.	To be agreed with Secretariat
Supplementary Immunisation Activity (SIA) technical report	Within 3 months of end of campaign
Post campaign coverage survey report	As soon as available

17. Financial clarifications: Not applicable

18. Other conditions: as a condition to Gavi's support for measles and rubella, Rwanda will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

13 June 2017